Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Adagrasib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 179,460Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Trends in OPDP Research and Recent Enforcement Actions
    Trends in OPDP Research and Recent Enforcement Actions

    16 May 2025

    // RAPS

    https://www.raps.org/news-and-articles/news-articles/2025/5/trends-in-opdp-research-and-recent-enforcement-act

    RAPS
    16 May 2025
    Share Share
    US FDA approves Bristol Myers' colorectal cancer therapy
    US FDA approves Bristol Myers' colorectal cancer therapy

    22 Jun 2024

    // Christy Santhosh REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-bristol-myers-colorectal-cancer-therapy-2024-06-21/

    Christy Santhosh REUTERS
    22 Jun 2024
    Share Share
    ASCO: KRAS upstarts set their sights on NSCLC market
    ASCO: KRAS upstarts set their sights on NSCLC market

    05 Jun 2024

    // Phil Taylor PHARMAPHORUM

    https://pharmaphorum.com/news/asco-kras-upstarts-set-their-sights-nsclc-market

    Phil Taylor PHARMAPHORUM
    05 Jun 2024
    Share Share
    KRAZATI Improves PFS In Pretreated KRAS G12C Mutant NSCLC
    KRAZATI Improves PFS In Pretreated KRAS G12C Mutant NSCLC

    01 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240531926564/en

    BUSINESSWIRE
    01 Jun 2024
    Share Share
    KRAZATI with Cetuximab Demonstrates Clinically Meaningful Activity
    KRAZATI with Cetuximab Demonstrates Clinically Meaningful Activity

    08 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240407754891/en

    BUSINESSWIRE
    08 Apr 2024
    Share Share
    Zai Lab Partner BMS Announces Trial KRAZATI (adagrasib) Meets Primary Endpoint
    Zai Lab Partner BMS Announces Trial KRAZATI (adagrasib) Meets Primary Endpoint

    01 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240401347225/en

    BUSINESSWIRE
    01 Apr 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.